Stunning Start For Vertex Cystic Fibrosis Triple Combo
Trikafta Shatters Forecasts With Q4 $420m Sales
Only nine weeks after US approval, Trikafta, which in theory can treat 90% of all patients with cystic fibrosis, is already Vertex's top-selling medicine.
You may also be interested in...
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
The reimbursement deal will allow cystic fibrosis patients as young as two years of age to access Orkambi in France for the first time.
After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.